Mazdutide: dose range, storage & handling reference
Also known as: IBI362, LY3305677, GLP-1/glucagon dual agonist
Quick answer
What is Mazdutide?
A GLP-1 + glucagon dual agonist in trials for weight loss with an added energy-burn component.
Mazdutide at a glance
| Dose range referenced | Research literature commonly references escalating weekly amounts studied across roughly the ~3–9 mg/week range in trials |
| Studied for | Metabolic and weight-management research |
| Route referenced in research | Subcutaneous (research) |
| Half-life | ~4–7 days (reported) |
| Storage | Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data. |
The dose range above describes figures referenced in research literature. It is not a recommendation.
What Mazdutide is stacked with in research
Referenced in research as a single dual-agonist molecule; combining with other incretin agents is not standard in the literature.
Side effects observed in research
- Nausea
- Reduced appetite
- Diarrhea
- Gastrointestinal upset
Reconstituting Mazdutide
Concentration is vial contents divided by water added, whatever the compound: a 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL. The step-by-step reconstitution guide works through the arithmetic, and the free calculator below returns exact syringe units.
This is a reference entry. An expanded profile — mechanism, cited literature, protocol tables and reconstitution math — is being added across the library.
Skip the Mazdutide math
Enter vial size, water volume, and target dose — the free calculator returns concentration, injection volume, and exact U-100 syringe units.
Source in Canada
COA-documented research compounds, sourced from Canada.
RegenBioSignals →Referral partner — we may earn a commission.
Related research peptides
Semaglutide
A GLP-1 receptor agonist studied and prescribed for glycemic control and weight management.
GLP-1 / MetabolicTirzepatide
A dual GIP/GLP-1 receptor agonist studied and prescribed for glycemic control and weight loss, generally outperforming semaglutide on weight loss in trials.
GLP-1 / MetabolicRetatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures of the class in Phase 2 trials (~24% at 48 weeks, 12 mg).
Browse all GLP-1 / Metabolic peptides or start with the beginner’s guide to research peptides.